Company Description
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Daniel Vitt |
Contact Details
Address: 1200 Avenue of the Americas, Suite 200 New York, New York 10036 United States | |
| Phone | 332 255 9818 |
| Website | imux.com |
Stock Details
| Ticker Symbol | IMUX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001280776 |
| CUSIP Number | 4525EP101 |
| ISIN Number | US4525EP1011 |
| Employer ID | 56-2358443 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel Vitt Ph.D. | Chief Executive Officer and Director |
| Dr. Duane D. Nash J.D., M.B.A., M.D. | Executive Chairman |
| Jason Tardio M.B.A. | Chief Operating Officer and President |
| Glenn Whaley CPA | Chief Financial Officer |
| Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer |
| Dr. Hella Kohlhof | Chief Scientific Officer |
| Jessica Breu | Head of Investor Relations and Communications |
| Inderpal Singh | General Counsel |
| Patrick Walsh | Chief Business Officer |
| Werner Gladdines | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 8-K | Current Report |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2025 | 424B5 | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |